Abstract:6011 Background: The excision repair cross-complementation group 1 (ERCC1) enzyme is a key element of the nucleotide excision repair (NER) pathway which removes cisplatin-induced DNA adducts and has been associated with resistance to platinum-based chemotherapy. We assessed the correlation of ERCC1 immunohistochemical expression with objective tumor response and cancer-specific survival in patients with locally advanced head and neck squamous-cell carcinoma (HNSCC) treated with cisplatin-based induction chemotherapy (CBIC). Methods: The initial cohort comprised 107 patients who had received CBIC (modified Al Saraf protocol) from 1992 to 1996 for locally advanced HNSCC. P53 mutations had been previously studied. Pre-therapeutic biopsy samples from 96 patients with a known tumor response were available. Two independent observers blinded to clinical annotations evaluated ERCC1 expression using the H-score protocol. The median H-score value was a priori selected as the cutpoint in order to dichotomize ERCC1 expression for statistical analysis. Results: In 68 cases [71%, 95% CI: 61% - 79%] tumors expressed ERCC1 intensively and diffusely. Using the logistic regression method, the 28 patients [29 %, 95% CI:21%-39%] with tumors expressing ERCC1 at lower levels had a four time greater odds of benefiting from an objective response to chemotherapy [OR 4.3, 95% CI: 1.4 - 13.4; p = 0.01]. ERCC1 and p53 status, but not their association, were independent predictors of tumor response. In a Cox proportional hazard model adjusted on well-established prognosticators including age, T, N, M, tumor differentiation and localization, ERCC1 low expression was associated with a lower risk of cancer death [RR 2.13, 95% CI: 1.03 - 4.43; p=0.04], while p53 status had no prognostic value. Conclusions: Patients with ERCC1 negative tumors are more likely to derive a substantial benefit from CBIC, translated to a lower risk for cancer-related death compared to patients with ERCC1 positive tumors. Large prospective trials should evaluate ERCC1 and other critical biomarkers involved in DNA damage repair process as molecular predictors of responsiveness to chemotherapy in patients with HNSCC. No significant financial relationships to disclose.

Erythrocyte PIG‐A mutant frequencies in cancer patients receiving cisplatin

Mitochondrial Modulation by Epigallocatechin 3-Gallate Ameliorates Cisplatin Induced Renal Injury Through Decreasing Oxidative/nitrative Stress, Inflammation and NF-kB in Mice.

A Phase I/Ii and Pharmacogenomic Study of Pemetrexed and Cisplatin in Patients with Unresectable, Advanced Gastric Carcinoma

Measuring blood cell DNA damage using the PIG-A mutation and CBMN assay in pancreatic cancer patients: a pilot study

The in Vivo Pig-a Gene Mutation Assay is Applied to Study the Genotoxicity of Procarbazine Hydrochloride in Sprague-Dawley Rats

Differential methylation EPIC analysis discloses cisplatin-resistance related hypermethylation and tumor-specific heterogeneity within matched primary and metastatic testicular germ cell tumor patient tissue samples

PIG-A gene mutation as a mutagenicity biomarker among coke oven workers

Assessment of the In Vitro Phosphatidylinositol Glycan Class A (PIG-A) Gene Mutation Assay Using Human TK6 and Mouse Hepa1c1c7 Cell Lines

PIG‐A Gene Mutation As a Genotoxicity Biomarker in Human Population Studies: an Investigation in Lead‐exposed Workers

Phosphatidyl Inositol-3 Kinase (PIK3CA) E545K Mutation Confers Cisplatin Resistance and a Migratory Phenotype in Cervical Cancer Cells

Reduced Cisplatin Sensitivity Of Head And Neck Squamous Cell Carcinoma Cell Lines Correlates With Mutations Affecting The Cooh-Terminal Nuclear Localization Signal Of P53

Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer

Sensitization To The Cytotoxicity Of Cisplatin By Transfection With Nucleotide Excision Repair Gene Xeroderma Pigmentosun Group A Antisense Rna In Human Lung Adenocarcinoma Cells

XPA tumor variant leads to defects in NER that sensitize cells to cisplatin

Ghrelin Prevents Cisplatin-Induced Testicular Damage by Facilitating Repair of DNA Double Strand Breaks Through Activation of p53 in Mice

PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy

Microrna-302a Sensitizes Testicular Embryonal Carcinoma Cells to Cisplatin-Induced Cell Death

Application of the in Vivo Pig-a Gene Mutation Assay to Test the Potential Genotoxicity of P-Phenylenediamine.

Ercc1 Immunohistochemical Expression And Cancer-Specific Survival In Patients With Locally Advanced Squamous-Cell Carcinoma Of The Head And Neck Treated By Cisplatin-Based Induction Chemotherapy

The efficacy of theophylline in preventing cisplatin-related nephrotoxicity in patients with cancer

Assessment of the Pig-a, micronucleus, and comet assay endpoints in rats treated by acute or repeated dosing protocols with procarbazine hydrochloride and ethyl carbamate.